Literature DB >> 34756649

Severe Acute Cellular Rejection With High-Grade Lymphocytic Bronchiolitis Following Transition from Tacrolimus to Belatacept in a Lung Transplantation Recipient: A Case Report.

Arun Nachiappan1, Tara Fallah2, Rebecca Willert2, Donna Chojnowski2, Charuhas Deshpande3, Andrew Courtwright4.   

Abstract

This case report describes a lung transplantation recipient who developed severe acute cellular rejection with high-grade lymphocytic bronchiolitis after transition to a calcineurin-free regimen using belatacept. A 53-year-old man who had undergone lung transplantation 3 years prior developed progressive chronic kidney disease related to tacrolimus. He was transitioned off tacrolimus to belatacept to prevent the need for dialysis. He was admitted 2 months later with acute hypoxemic respiratory failure. Video-assisted thoracic surgery biopsy showed acute fibrinous and organizing pneumonia and A4B2 rejection. He subsequently developed chronic lung allograft dysfunction. This case illustrates the potential increased risk of acute rejection associated with belatacept maintenance immunosuppression.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34756649     DOI: 10.1016/j.transproceed.2021.08.051

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation.

Authors:  Howard J Huang; Kenneth Schechtman; Medhat Askar; Cory Bernadt; Brigitte Mittler; Peter Dore; Chad Witt; Derek Byers; Rodrigo Vazquez-Guillamet; Laura Halverson; Ruben Nava; Varun Puri; Andrew Gelman; Daniel Kreisel; Ramsey R Hachem
Journal:  Am J Transplant       Date:  2022-03-22       Impact factor: 9.369

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.